EIPA
EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3) . EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma[1][2][3][4][5][6][7].
Product Specifications
CAS Number
[1154-25-2]
Product Name Alternative
L593754; MH 12-43; Ethylisopropylamiloride
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; COX; Na+/H+ Exchanger (NHE) ; Prostaglandin Receptor; TRP Channel
Type
Reference compound
Related Pathways
Autophagy; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/EIPA.html
Concentration
10mM
Purity
99.73
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
O=C(C1=NC(Cl)=C(N(CC)C(C)C)N=C1N)NC(N)=N
Molecular Formula
C11H18ClN7O
Molecular Weight
299.76
Precautions
H302, H315, H319, H335
References & Citations
[1]Dai XQ, et al. Inhibition of TRPP3 channel by MK-870 and analogs. Mol Pharmacol. 2007 Dec;72 (6) :1576-85.|[2]Shi H, et al. Na+/H+ Exchanger Regulates Amino Acid-Mediated Autophagy in Intestinal Epithelial Cells. Cell Physiol Biochem. 2017;42 (6) :2418-2429.|[3]Zhu BY, et al. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis.|[4]E V Stelmashook, et al. Acidosis and 5- (N-ethyl-N-isopropyl) amiloride (EIPA) Attenuate Zinc/Kainate Toxicity in Cultured Cerebellar Granule Neurons. Biochemistry (Mosc) . 2015 Aug;80 (8) :1065-72. |[5]Shigekuni Hosogi, et al. An inhibitor of Na (+) /H (+) exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl (-) concentration via DIDS-sensitive pathways. Cell Physiol Biochem. 2012;30 (5) :1241-53.|[6]Junji Yamashita, et al. Role of Na+/H+ exchanger in the pathogenesis of ischemic acute renal failure in mice. J Cardiovasc Pharmacol. 2007 Mar;49 (3) :154-60. |[7]Fumitaka Kamachi, et al. Inhibition of lipopolysaccharide-induced prostaglandin E2 production and inflammation by the Na+/H+ exchanger inhibitors. J Pharmacol Exp Ther. 2007 Apr;321 (1) :345-52.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
COX-2
Citation 01
ACS Appl Mater Interfaces. 2020 Oct 14;12 (41) :45763-45771.|ACS Nano. 2020 Nov 24;14 (11) :14698-14714.|ACS Nano. 2024 Sep 11.|ACS Nano. 2025 Aug 19;19 (32) :29341-29359.|Adv Funct Mater. 2021 Apr 1.|Adv Healthc Mater. 2025 Jul 9:e2500592.|Adv Healthc Mater. 2025 May 19:e2500546.|Adv Healthc Mater. 2025 May 24:e2500507.|Adv Mater. 2025 Jan 10:e2415030.|Adv Sci (Weinh) . 2024 Nov 6:e2412014.|Adv Sci (Weinh) . 2025 Mar 27:e2415684.|Adv Sci (Weinh) . 2025 Sep 3:e02788.|Anal Chem. 2020 Jan 21;92 (2) :2103-2111.|Autophagy. 2023 Mar;19 (3) :839-857.|Biochim Biophys Acta Gen Subj. 2023 Mar;1867 (3) :130300.|Biol Open. 2023 Nov 15;12 (11) :bio060081.|Biomacromolecules. 2021 Sep 13;22 (9) :3679-3691.|Biomaterials. 2022 Feb:281:121373.|Bioorg Chem. 2022 Apr:121:105651.|bioRxiv. 2024 Jan 10:2024.01.07.574541.|bioRxiv. 2025 May 3:2025.04.29.651251.|bioRxiv. 2025 Nov 20.|Biotechnol J. 2023 Feb;18 (2) :e2200393.|BMC Plant Biol. 2025 Feb 7;25 (1) :159.|Bone Res. 2025 Oct 20;13 (1) :88.|Cancer Drug Resist. 2025 Aug 27:8:45.|Cancer Res. 2025 Jul 15;85 (14) :2659-2678.|Cancer Res. 2025 Oct 9.|Carbohydr Polym. 2025 Nov 15;368 (Pt 1) :124067.|Carcinogenesis. 2024 Jul 15:bgae045.|Cell Death Dis. 2025 Apr 5;16 (1) :253.|Cell Metab. 2022 Dec 6;34 (12) :2018-2035.e8.|Chem Eng J. 2024 Sep 1.|Clin Transl Med. 2025 Jan;15 (1) :e70191.|Comput Struct Biotechnol J. 2021;19:1933-1943.|Drug Deliv. 2021 Dec;28 (1) :800-813.|Eur J Pharm Sci. 2025 Sep 1:212:107188.|Exp Hematol. 2024 Dec:140:104651.|Genes Dev. 2021 Oct 1;35 (19-20) :1327-1332.|Int Immunopharmacol. 2025 May 30:160:114918.|Int J Biol Macromol. 2025 Apr 28;310 (Pt 4) :143599.|Int J Mol Sci. 2025 Mar 29;26 (7) :3172.|iScience. 2023 Apr 7;26 (5) :106598.|J Biol Chem. 2022 Nov;298 (11) :102511.|J Control Release. 2022 Nov:351:703-712.|J Control Release. 2023 Mar:355:675-684.|J Control Release. 2024 Jun:370:140-151.|J Control Release. 2025 Aug 29:387:114176.|J Control Release. 2025 Jun 6:113939.|J Exp Med. 2023 Mar 6;220 (3) :e20221316.|J Hazard Mater. 2021 Sep 5;417:126092.|J Nanobiotechnology. 2022 Jun 10;20 (1) :268.|J Neuroinflammation. 2024 May 10;21 (1) :125.|J Pathol. 2023 May;260 (1) :17-31.|J Virol. 2021 Nov 23;95 (24) :e0134521.|J Virol. 2025 Aug 25:e0022125.|Mater Today Bio. 2025 Nov 13:35:102547.|Matter. 2023 Aug 31.|Microb Pathog. 2025 May 26:206:107751.|Microvasc Res. 2021 Nov:138:104219.|Nanotoxicology. 2022 Nov-Dec;16 (9-10) :895-912.|Nat Commun. 2024 Jan 2;15 (1) :162.|Nat Commun. 2025 Feb 4;16 (1) :1327.|Nat Commun. 2025 Sep 26;16 (1) :8522.|Nat Nanotechnol. 2025 Feb;20 (2) :296-302.|Pharmaceutics. 2020 Feb 17;12 (2) :167.|Pharmaceutics. 2024 Nov 21.|PLoS Pathog. 2024 Nov 21;20 (11) :e1012681.|Polym Sci Technol. 2025 Sep 15.|Sci Adv. 2020 Aug 12;6 (33) :eaaz1774.|Sci China Life Sci. 2022 Feb;65 (2) :341-361.|Sci China Mater. 63, 620-628 (2020) .|Signal Transduct Target Ther. 2025 Oct 21;10 (1) :349.|SSRN. 2025 Sep 30.|Theranostics. 2022 Jan 1;12 (3) :1061-1073.|Vet Res. 2023 Mar 14;54 (1) :24.|Viruses. 2021 May 31;13 (6) :1035.|Acta Biomater. 2024 Feb:175:250-261.|Cancer Cell. 2025 Jul 15:S1535-6108 (25) 00271-5.|Emerg Microbes Infect. 2022 Dec;11 (1) :1135-1144.|J Cell Biol. 2025 May 5;224 (5) :e202405060.|J Nanobiotechnology. 2022 Jul 20;20 (1) :340.|Mol Pharm. 2021 Oct 4;18 (10) :3750-3762.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15380612 1 Vial
Lentiviral human USP46 sgRNA gene knockout kit - Lentiviral human USP46 sgRNA gene knockout kit (plasmid)
Ask
View Details 